Valuation: Profound Medical Corp.

Market Cap 346M 250M 215M 201M 184M 23.97B 350M 2.38B 924M 12.04B 940M 920M 39.83B P/E 2026 *
-7.9x
P/E 2027 * -11.6x
Enterprise Value 346M 250M 215M 201M 184M 23.97B 350M 2.38B 924M 12.04B 940M 920M 39.83B EV / Sales 2026 *
9.56x
EV / Sales 2027 * 5.82x
Free-Float
95.91%
Yield 2026 *
-
Yield 2027 * -
1 day+1.72%
1 week+3.04%
Current month-8.67%
1 month-7.78%
3 months-0.32%
6 months-1.86%
Current year-11.98%
1 week 9.06
Extreme 9.06
10.07
1 month 9.03
Extreme 9.03
11.98
Current year 6.52
Extreme 6.52
12.4
1 year 5.23
Extreme 5.23
12.4
3 years 5.23
Extreme 5.23
16
5 years 4.21
Extreme 4.21
20.61
10 years 4.21
Extreme 4.21
36.73
Manager TitleAgeSince
Chief Executive Officer 71 14/08/2016
Director of Finance/CFO - 13/08/2026
President 44 06/11/2024
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 13/06/2018
Director/Board Member 79 13/06/2018
Date Insider Type Main position Quantity % Market Cap.
17/08/26 Buy

Executive/Senior Manager

3,755 0.0103%
14/08/26 Other

Chief Financial Officer

0 0%
14/08/26 Other

Chief Financial Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+1.72%+3.04%+44.07%-13.03% 250M
-0.08%+7.38%+25.75%+16.86% 232B
-1.71%+6.16%+1.56%-15.16% 151B
-1.38%-4.29%-21.55%+30.78% 132B
-2.70%-4.71%-53.84%-2.82% 71.03B
-1.13%+1.37%-15.86%-11.95% 52.46B
+0.79%-0.34%+10.60%+20.65% 52.16B
-3.50%+3.35%+26.14%+28.40% 43.33B
+0.01%+0.74%+35.92%+51.47% 40.36B
-0.84%+2.51%-1.37%+8.42% 33.51B
Average -0.69%+1.95%+5.14%+11.36% 80.88B
Weighted average by Cap. -0.74%+2.78%+2.26%+11.78%

Financials

2026 *2027 *
Net sales 36.22M 26.18M 22.44M 20.99M 19.19M 2.51B 36.6M 248M 96.58M 1.26B 98.31M 96.18M 4.17B 59.46M 42.98M 36.84M 34.46M 31.51M 4.12B 60.09M 408M 159M 2.07B 161M 158M 6.84B
Net income -44.08M -31.87M -27.31M -25.55M -23.36M -3.05B -44.55M -302M -118M -1.53B -120M -117M -5.07B -31.27M -22.6M -19.37M -18.12M -16.57M -2.16B -31.6M -214M -83.38M -1.09B -84.87M -83.03M -3.6B
Net Debt - -
Logo Profound Medical Corp.
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
162
Date Price Change Volume
24/08/26 CA$9.480 +1.72% 5,603
21/08/26 CA$9.320 +2.42% 1,517
20/08/26 CA$9.100 -6.67% 12,241
19/08/26 CA$9.750 -0.10% 6,206
18/08/26 CA$9.760 +6.09% 10,634
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
9.480
Average target price
-

Quarterly revenue - Rate of surprise